Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

Authors

Carlo Gambacorti-Passerini, University of Milano Bicocca
Brian A. Van Tine, Washington University School of Medicine in St. Louis
et al

Journal

American Journal of Hematology

Publication Date

2018

Volume

93

First Page

607

Last Page

614

Document Type

Open Access Publication

DOI

10.1002/ajh.25043

Rights and Permissions

Gambacorti‐Passerini, C, Orlov, S, Zhang, L, et al. Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study. Am J Hematol. 2018; 93: 607– 614. https://doi.org/10.1002/ajh.25043 © 2018 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

Recommended Citation

Gambacorti-Passerini, Carlo; Van Tine, Brian A.; and et al, "Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study." American Journal of Hematology. 93, 607 - 614. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/8184